GleamWall
中文EN

RLMD RELMADA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1553643 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY59.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.7%
ROA-59.7%
ROIC (approx.)-54.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio26.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$26.88M$46.18M
SG&A expense$32.22M$37.72M
Operating income-$59.10M-$83.89M
Net income-$57.39M-$79.98M
EPS (basic)-1.45-2.65
EPS (diluted)-1.45-2.65
Weighted avg. shares (diluted)39.48M30.16M
Balance sheet
Cash & equivalents$3.50M$3.86M
Short-term investments$89.51M$41.05M
Current assets$93.98M$45.80M
Total assets$94.00M$45.82M
Current liabilities$6.43M$10.29M
Total liabilities$7.49M$10.30M
Shareholders' equity$86.51M$35.52M
Shares outstanding73.33M30.17M
Cash flow statement
Operating cash flow-$45.79M-$51.76M
Investing cash flow-$48.14M$51.56M
Financing cash flow$93.56M-$40,341
Stock-based compensation$13.91M$30.18M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.